RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution

7 Dec 2023

Amsterdam, Netherlands, December 7th 2023 — RxLogix Corporation, a global leading provider of end-to-end Safety and Pharmacovigilance (PV) Software and Services, is delighted to announce a strategic software agreement with the European Medicines Agency (EMA) to begin the development of the new Signal and Safety Analytics (SSA) platform.

The SSA platform, which will include RxLogix PV Signal, PV Reports and PV analytics, is poised to bring about a significant improvement in a number of processes underpinning the signal detection and validation activities performed by the Agency and the European Medicines Regulatory Network (EMRN). The software agreement is a testament to RxLogix Corporation’s dedication to fostering innovation and delivering high-quality solutions that address the evolving needs of regulatory authorities.

RxLogix PV Signal is the industry’s most complete signal detection and management platform that provides a dynamic data mining and data analytics environment for detecting signals, uncovering patterns, and recognizing emerging trends in adverse event report data. RxLogix PV Reports is the most advanced, user-friendly, and self-service tool for Regulatory Reports, Ad-hoc Reports, with out-of-the-box visualizations and data exploration capabilities.

The software agreement between RxLogix Corporation and EMA underscores our unwavering commitment to advancing pharmacovigilance, data management, and regulatory excellence. The ultimate aim is to contribute to the safety of medicinal products within the European Economic Area.

“We at RxLogix are excited and proud to be undertaking this partnership with EMA to deliver and implement our integrated reporting, analytics & signal detection solution for the new SSA platform. We see ourselves as the pharmacovigilance and drug safety platform of choice for the pharma companies and regulatory agencies alike globally; being trusted and chosen by EMA to deliver this work truly demonstrates our pedigree in this field”. said Raj More, Chief Architect & CEO at RxLogix.

For additional information, interviews, or inquiries, please contact:

Mark Parker

RxLogix Corporation


Supporting Information

PV Signal – https://www.rxlogix.com/pv-surveillance/pv-signal/

PV Reports – https://www.rxlogix.com/pv-surveillance/pv-reports/

About RxLogix Corporation

RxLogix is a global pharmacovigilance solutions company specializing in innovative software and expert consulting services. Our talented team of business and technology innovators works with Pharmacovigilance and Risk Management Professionals to help increase the compliance, productivity, and quality for the entire Drug Safety value chain. We are business transformers, digital thinkers, tech Innovators, technology revolutionist, business mavericks, driven and open-minded individuals. At RxLogix, our goal is to make the most innovative industry standard software for the life sciences domain.


About EMA

The European Medicines Agency (EMA) is a decentralized agency of the European Union entrusted with the scientific evaluation, supervision, and safety monitoring of medicinal products within the EU. EMA’s mission is rooted in safeguarding and promoting public health by ensuring the safety, efficacy, and quality of medicines across the European Union.



 RxLogix, PV Signal, and PV Reports are registered trademarks of RxLogix Corporation. Other names may be trademarks of their respective owners.